



P A T E N T

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Gene Samson et al. Confirmation No.: 6911
Serial No.: 09/648,378 Examiner: V. Bui
Filing Date: August 25, 2000 Group Art Unit: 3731
Docket No.: 1001.1585104 Customer No.: 28075
For: HIGH PERFORMANCE BRAIDED CATHETER

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RECEIVED
MAY 05 2004
TECHNOLOGY CENTER R3701G

TERMINAL DISCLAIMER TO OBVIATE DOUBLE PATENTING
REJECTION OVER A PRIOR PATENT (37 C.F.R. 1.321(c))

CERTIFICATE UNDER 37 C.F.R. 1.10: The undersigned hereby certified that this paper or papers, as described herein are being deposited in the United States Postal Service, "Express Mail Post Office to Addressee" having an Express Mail mailing label number of: EV 315613878 US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 30th day of April 2004.

By Kathleen L. Boekley
Kathleen L. Boekley

The owner, Target Therapeutics, Inc., of full interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 5,891,112. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

05/03/2004 HBL/DCD 00000009 09648378

01 FC:1814

110.00 OP

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.


The undersigned is an attorney of record.

The terminal disclaimer fee under 37 C.F.R. § 1.20(d) is included.

Respectfully submitted,

Target Therapeutics, Inc.

By its Attorney,



David M. Crompton, Reg. No. 36,772
CROMPTON, SEAGER & TUFTE, LLC
1221 Nicollet Avenue, Suite 800
Minneapolis, Minnesota 55403-2420
Telephone: (612) 677-9050
Facsimile: (612) 359-9349

Date: _____

4/30/04